Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer
2023 · New England Journal of Medicine · 336 citations
https://doi.org/10.1056/nejmoa2309169
A
Antoine Angelergues
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
60
Papers
980
Citations
12
h-index
14
i10-index
Antoine Angelergues is an academic researcher from Groupe Hospitalier Diaconesses Croix Saint-Simon. The author has contributed to research in topics: Prostate Cancer Treatment and Research & Cancer Immunotherapy and Biomarkers & Cancer Treatment and Pharmacology. The author has an h-index of 12, co-authored 51 publications.
ORCID: 0009-0005-4876-918XPapers by this author
worksCirculating tumor DNA strongly predicts efficacy of chemotherapy plus immune checkpoint inhibitors in patients with advanced gastro-esophageal adenocarcinoma
2025 · Communications Medicine · 6 citations
https://doi.org/10.1038/s43856-025-00867-x
TEDOVA: vaccine OSE2101 +/- pembrolizumab as maintenance in platinum-sensitive recurrent ovarian cancer
2024 · Future Oncology · 0 citations
https://doi.org/10.1080/14796694.2024.2386922
Resection of colorectal liver metastases with second-line aflibercept plus FOLFIRI: Results from the RESECTION prospective French cohort
2024 · European Journal of Cancer · 0 citations
https://doi.org/10.1016/j.ejca.2024.115082
Genomic Characterization Of Gynaecological Carcinosarcoma: Analysis Of The Initial Cohorts From ROCSAN Phase II/III Trial From GINECO Group
2025 · International Journal of Gynecological Cancer · 0 citations
https://doi.org/10.1016/j.ijgc.2024.100394
Recommandations pour la pratique clinique Nice/Saint-Paul-de-Vence 2024–2025 : prise en charge du cancer de l’endomètre métastatique et/ou en rechute
2026 · Bulletin du Cancer · 0 citations
https://doi.org/10.1016/j.bulcan.2026.01.001
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat